Aquestive Therapeutics, Inc.
—- Market cap
- $670.23M
- Debt
- +$45.00M
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 94% equity / 6% debt
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: AQST stock price at premium vs MYRG $5.34 current versus $0.43 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MYRG's multiple
Implied fair value · at AQST's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AQST FY 2025 (ended Dec 31, 2025) · MYRG FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 94% equity / 6% debt
Capital structure 99% equity / 1% debt · EV / Revenue 1.20x · EV / EBITDA 18.34x
MYRG carries the larger enterprise value at $4.38B against $715.23M; MYRG trades on the lower EV / Revenue multiple (1.20x vs 16.06x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Aquestive Therapeutics, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
MYR GROUP INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-1.34x
0.10x
Net debt / EBITDA
Leverage against operating earnings
—
-0.36x
Cash and equivalents
Liquid reserves on the balance sheet
—
$150.16M
Total debt
Interest-bearing obligations outstanding
$45.00M
$63.59M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.